Lot-to-lot consistency study of an Escherichia coli-produced bivalent human papillomavirus vaccine in adult women: a randomized trial

An Escherichia. coli-produced HPV-16/18 bivalent vaccine has been proved to be well-tolerated and highly efficacious against diseases associated with vaccine HPV types. As a part of the multi-center, randomized, double-blind phase III clinical trial, this lot-to-lot consistency study aimed to assess...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Ying-Ying Su, Bi-Zhen Lin, Hui Zhao, Juan Li, Zhi-Jie Lin, You-Lin Qiao, Li-Hui Wei, Yue-Mei Hu, Rong-Cheng Li, Si-Jie Zhuang, Guang Sun, Zi-Zheng Zheng, Shou-Jie Huang, Ting Wu, Jun Zhang, Hui-Rong Pan, Chang-Gui Li
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-07-01
Subjects:	human papillomavirus vaccine escherichia coli bivalent lot-to-lot consistency immunogenicity safety
Online Access:	http://dx.doi.org/10.1080/21645515.2019.1691413